Use: Labeled indications
- Venofer is indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD).
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Venofer is indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD). Venofer is an iron replacement product indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD). (1)
Contraindications
4 CONTRAINDICATIONS Known hypersensitivity to Venofer. Known hypersensitivity to Venofer (4)
US FDA labelDosing: Adult
- Venofer must only be administered intravenously either by slow injection or by infusion. The dosage of Venofer is expressed in mg of elemental iron. Each mL contains 20 mg of elemental iron. Population Dose Adult patients Hemodialysis Dependent-Chronic Kidney Disease (HDD-CKD) (2.2)
- 100 mg slow intravenous injection or infusion Non-Dialysis Dependent-Chronic Kidney Disease (NDD-CKD) (2.3)
- 200 mg slow intravenous injection or infusion Peritoneal Dialysis Dependent-Chronic Kidney Disease (PDD-CKD) (2.4)
- 300 mg or 400 mg intravenous infusion Pediatric patients HDD-CKD (2.5), PDD-CKD or NDD-CKD (2.6)
- 0.5 mg/kg slow intravenous injection or infusion
2.1 Mode of Administration
2.1 Mode of Administration Administer Venofer only intravenously by slow injection or by infusion. The dosage of Venofer is expressed in mg of elemental iron. Each mL contains 20 mg of elemental iron.
2.2 Adult Patients with Hemodialysis Dependent-Chronic Kidney Disease (HDD-CKD)
2.2 Adult Patients with Hemodialysis Dependent-Chronic Kidney Disease (HDD-CKD) Administer Venofer 100 mg undiluted as a slow intravenous injection over 2 to 5 minutes, or as an infusion of 100 mg diluted in a maximum of 100 mL of 0.9% NaCl over a period of at least 15 minutes, per consecutive hemodialysis session [see How Supplied/Storage and Handling (16.2).] Administer Venofer early during the dialysis session (generally within the first hour). The usual total treatment course of Venofer is 1000 mg.
Venofer treatment may be repeated if iron deficiency reoccurs.
2.3 Adult Patients with Non-Dialysis Dependent-Chronic Kidney Disease (NDD-CKD)
2.3 Adult Patients with Non-Dialysis Dependent-Chronic Kidney Disease (NDD-CKD) Administer Venofer 200 mg undiluted as a slow intravenous injection over 2 to 5 minutes or as an infusion of 200 mg in a maximum of 100 mL of 0.9% NaCl over a period of 15 minutes. Administer on 5 different occasions over a 14 day period. There is limited experience with administration of an infusion of 500 mg of Venofer, diluted in a maximum of 250 mL of 0.9% NaCl, over a period of 3.5 to 4 hours on Day 1 and Day 14 [see How Supplied/Storage and Handling (16.2).] Venofer treatment may be repeated if iron deficiency reoccurs.
2.4 Adult Patients with Peritoneal Dialysis Dependent-Chronic Kidney Disease (PDD-CKD)
2.4 Adult Patients with Peritoneal Dialysis Dependent-Chronic Kidney Disease (PDD-CKD) Administer Venofer in 3 divided doses, given by slow intravenous infusion, within a 28 day period: 2 infusions each of 300 mg over 1.5 hours 14 days apart followed by one 400 mg infusion over 2.5 hours 14 days later. Dilute Venofer in a maximum of 250 mL of 0.9% NaCl [see How Supplied/Storage and Handling (16.2).] Venofer treatment may be repeated if iron deficiency reoccurs.
2.5 Pediatric Patients (2 Years of Age and Older) with HDD-CKD for Iron Maintenance Treatment
2.5 Pediatric Patients (2 Years of Age and Older) with HDD-CKD for Iron Maintenance Treatment For iron maintenance treatment: Administer Venofer at a dose of 0.5 mg/kg, not to exceed 100 mg per dose, every two weeks for 12 weeks given undiluted by slow intravenous injection over 5 minutes or diluted in 0.9% NaCl at a concentration of 1 to 2 mg/mL and administered over 5 to 60 minutes. Do not dilute to concentrations below 1 mg/mL [see How Supplied/Storage and Handling [16.2].) Venofer treatment may be repeated if necessary.
The dosing for iron replacement treatment in pediatric patients with HDD-CKD has not been established.
2.6 Pediatric Patients (2 Years of Age and Older) with NDD-CKD
2.6 Pediatric Patients (2 Years of Age and Older) with NDD-CKD or PDD-CKD who are on Erythropoietin Therapy for Iron Maintenance Treatment For iron maintenance treatment: Administer Venofer at a dose of 0.5 mg/kg, not to exceed 100 mg per dose, every four weeks for 12 weeks given undiluted by slow intravenous injection over 5 minutes or diluted in 0.9% NaCl at a concentration of 1 to 2 mg/mL and administered over 5 to 60 minutes. Do not dilute to concentrations below 1 mg/mL [see How Supplied/Storage and Handling (16.2).] Venofer treatment may be repeated if necessary.
The dosing for iron replacement treatment in pediatric patients with NDD-CKD or PDD-CKD has not been established.
Dosing: Altered kidney function
2.2 Adult Patients with Hemodialysis Dependent-Chronic Kidney Disease (HDD-CKD) Administer Venofer 100 mg undiluted as a slow intravenous injection over 2 to 5 minutes, or as an infusion of 100 mg diluted in a maximum of 100 mL of 0.9% NaCl over a period of at least 15 minutes, per consecutive hemodialysis session [see How Supplied/Storage and Handling (16.2).] Administer Venofer early during the dialysis session (generally within the first hour). The usual total treatment course of Venofer is 1000 mg. Venofer treatment may be repeated if iron deficiency reoccurs.
2.3 Adult Patients with Non-Dialysis Dependent-Chronic Kidney Disease (NDD-CKD) Administer Venofer 200 mg undiluted as a slow intravenous injection over 2 to 5 minutes or as an infusion of 200 mg in a maximum of 100 mL of 0.9% NaCl over a period of 15 minutes. Administer on 5 different occasions over a 14 day period. There is limited experience with administration of an infusion of 500 mg of Venofer, diluted in a maximum of 250 mL of 0.9% NaCl, over a period of 3.5 to 4 hours on Day 1 and Day 14 [see How Supplied/Storage and Handling (16.2).] Venofer treatment may be repeated if iron deficiency reoccurs.
2.4 Adult Patients with Peritoneal Dialysis Dependent-Chronic Kidney Disease (PDD-CKD) Administer Venofer in 3 divided doses, given by slow intravenous infusion, within a 28 day period: 2 infusions each of 300 mg over 1.5 hours 14 days apart followed by one 400 mg infusion over 2.5 hours 14 days later. Dilute Venofer in a maximum of 250 mL of 0.9% NaCl [see How Supplied/Storage and Handling (16.2).] Venofer treatment may be repeated if iron deficiency reoccurs.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Safety and effectiveness of Venofer for iron replacement treatment in pediatric patients with dialysis-dependent or non-dialysis-dependent CKD have not been established. Safety and effectiveness of Venofer for iron maintenance treatment in pediatric patients 2 years of age and older with dialysis-dependent or non-dialysis-dependent CKD receiving erythropoietin therapy were studied.
Venofer at doses of 0.5 mg/kg, 1 mg/kg, and 2 mg/kg was administered. All three doses maintained hemoglobin between 10.5 g/dL and 14.0 g/dL in about 50% of subjects over the 12-week treatment period with stable EPO dosing [see Clinical Studies (14.7)]. Venofer has not been studied in patients younger than 2 years of age.
In a country where Venofer is available for use in children, at a single site, five premature infants (weight less than 1,250 g) developed necrotizing enterocolitis and two of the five died during or following a period when they received Venofer, several other medications and erythropoietin. Necrotizing enterocolitis may be a complication of prematurity in very low birth weight infants.
No causal relationship to Venofer or any other drugs could be established.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Of the 1,051 patients in two post-marketing safety studies of Venofer, 40% were 65 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
In general, dose administration to an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Administration
2.1 Mode of Administration Administer Venofer only intravenously by slow injection or by infusion. The dosage of Venofer is expressed in mg of elemental iron. Each mL contains 20 mg of elemental iron.
US FDA labelDosage forms
Philippines
- ) solution for injection: 20 mg/mL ( 100 mg/5 mL, 20 mg/mL (100 mg/5 mL, 20 mg/mL(100 Mg/5 mL
- Solution for injection: 20 mg/mL, 100 mg/5 mL
- Solution for intravenous injection: 20 mg/mL
- ) concentrate for solution for injection: 20 mg/mL (100 mg/5 mL
- ) solution for i.v. injection: 20 mg/mL (100 mg/5 mL
- ) solution for iv injection: 20 mg/mL (100 mg/5 mL
- ) lyophilized powder for injection: 20 mg/mL (100 mg/5 mL
- ) solution: 20 mg/mL (100 mg/5 mL
- ) solution for intravenous infusion: 20 mg/mL (100 mg/5 mL
- Elemental iron) solution for injection: 363.64 mg/mL (equivalent to 20 mg
Registered products in the Philippines
75 products registered with the Food and Drug Administration (FDA) Philippines list Iron sucrose as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products75
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AeferoseIron (as Iron sucrose) | 20 mg/mL Solution for Injection (IV)USP Type I Amber Glass Ampoule x 5 mL (Box of 5’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant III – Injectables)India | Dynasty PharmaceuticalsImporter: Ambica International CorporationTrader: Unosource Pharma Limited | DRP-10886-01 | Dec 8, 2037 | |
AnemaIron Sucrose | 20 mg/mL (100 mg/5 mL) Solution for Injection (IV)USP Type I Clear Colorless Glass Ampoule x 5mL (Box of 5's) | Rx | Gland Pharma LimitedIndia | Corbridge Group Phils. Inc.Importer: Biocare Lifesciences, Inc. | DRP-5540 | Jul 8, 2030 | |
AnemlesIron (as Iron Sucrose) | 20 mg/mL (100 mg/5 mL) Solution for Injection (IV)USP Type I amber glass ampoule in PVC plastic tray x 5 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Afree Pharmaceutical Distribution Corp. | DRP-13888 | May 11, 2028 | |
BiferronIron (as Iron Sucrose) | 20 mg/mL (100 mg/5 mL) SolutionAmber Type I Glass Ampoule with Blue Ring on Neck x 5 mL (Box of 5’s) | Rx | Kwality Pharmaceuticals Ltd.India | Pharma-Surrey International, Inc. | DRP-16388 | Feb 26, 2030 | |
BioroseIron (as Iron Sucrose) | 100 mg/5 mL Solution for Injection (I.V.)USP Type I Amber Glass Ampoule x 5 mL (Box of 5's) | Rx | Swiss Parenterals Ltd. (Block-B)India | Ambica International Corporation | DRP-7844 | Jan 26, 2028 | |
BlironIron (as Iron Sucrose) | 20 mg/ mL (100 mg/ 5 mL) Solution for Injection (IV)USP Type I amber glass ampoule in PVC plastic tray x 5 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp. | DRP-13888-03 | May 11, 2028 | |
BlironIron (as Ferric Hydroxide Sucrose Complex) | 20 mg/mL (100 mg/5 mL) Solution for Injection (IV)5mL USP Type I amber glass ampoule (Box of 5's) | Rx | Alwin DMD PharmaceuticalsIndia | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-7111 | Mar 17, 2027 | |
ClferIron (as Ferric Hydroxide Sucrose Complex) | 20 mg/mL (100mg/5mL) Solution for Injection (IV)5mL USP Type I amber glass ampoule (Box of 5's) | Rx | Alwin DMD PharmaceuticalsIndia | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-7111-05 | Mar 17, 2027 | |
DubesoneIron (as Iron sucrose) | 20 mg/mL Solution for Injection (IV)USP Type I Amber Glass Ampoule x 5 mL (Box of 5’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant III - Injectables)India | Ambica International CorporationTrader: Unosource Pharma Limited | DRP-10885 | Dec 29, 2031 | |
EnciferIron Sucrose | 20 mg/mL Solution for Injection (IV)5 mL USP Type I Transparent Flint Glass Ampoule (Box of 5's) | Rx | Emcure Pharmaceuticals LimitedIndia | Macropharma Corporation | DR-XY33701 | Aug 2, 2029 | |
EoferonIron (as Ferric Hydroxide Sucrose Complex) | 20 mg / mL (100 mg / 5 ml) Solution for Injection (IV)5 mL Amber Glass Ampoule (Box of 5’s) | Rx | Zee Laboratories LimitedHimachal Pradesh India | Eon Pharmatek Inc. | DRP-15056 | Oct 5, 2032 | |
EoferonIron (as Ferric Hydroxide Sucrose Complex) | 20 mg/mL (100 mg/5 mL) Solution for Injection (IV)5 mL Amber Glass Ampoule (Box of 5's) | Rx | Zee Laboratories LimitedIndia | Eon Pharmatek Inc. | DR-XY48363 | Oct 5, 2027 | |
EufercrosIron (as Iron Sucrose) | 100 mg/5 mL Solution for Injection (I.V.)USP Type I Amber Glass Ampoule x 5 mL (Box of 1 PVC Tray x 5's) | Rx | Swiss Parenterals Ltd. (Block-B)India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-7844-02 | Jan 26, 2028 | |
EvaferIron sucrose | 20 mg/mL (100 mg/5 mL) Solution for Injection (IV)USP Type I Clear Glass Ampoule x 5 mL in a Clear PVC Plastic Tray x 5's (Box of 5's) | Rx | Samrudh Pharmaceuticals Pvt. Ltd.India | Medethix, Inc.Importer: I.E. Medica, Inc. | DRP-7926-02 | Sep 2, 2031 | |
FeMaxIron (as Iron Sucrose) | 20 mg/mL Solution for Injection (IV)USP Type I Clear Glass Ampoule x 5 mL in a Plastic Tray x 5's (Box of 5's) | Rx | Gulf Pharmaceutical Industries (Julphar)United Arab Emirates | DéGa International Pharma Corp. | DR-XY43848 | Oct 30, 2029 | |
FemorumIron Sucrose | 20 mg/mL (100 mg/5 mL) Solution for IV InjectionUSP Type I Colorless Transparent Glass Ampoule x 5 mL (Box of 5's) | Rx | Myungmoon Pharmaceutical Co., Ltd.Republic of Korea | Central West Medicale Inc.Importer: H & B Pharma International Inc. | DR-XY43638 | Aug 18, 2029 | |
FenemikIron [as Ferric hydroxide sucrose complex] | 20 mg/mL (100 mg/5 mL) Concentrate for Solution for Injection (I.V. Infusion)5 mL amber-colored glass ampoule Type I (Box of 5's) | Rx | Mefar Ilac Sanayii A.S.Turkey | Ambica International CorporationTrader: Pharmada Ilac San. Ve Tic. A.S. | DRP-10294 | Sep 6, 2030 | |
FeravinIron Sucrose | 20 mg/mL Solution for Intravenous (I.V.) InjectionUSP Type I Amber Glass Ampoule x 5 mL (Box of 5's) | Rx | Mason PharmaIndia | MDB Pharma TradingImporter: Finstad Inc. | DRP-12662-01 | Sep 20, 2027 | |
FerogenIron Sucrose | 20 mg/mL ( 100 mg/5 mL) Solution for Injection (I.V.)USP Type I Amber Glass Ampoule x 5 mL Box of 1 's | Rx | Samarth Life Sciences Pvt. Ltd.India | NEXT CHEMICAL ENTERPRISES | DRP-6412 | Feb 28, 2029 | |
FeronIron (as sucrose) | 20 mg/mL (100 mg/5 mL) Solution for I.V. Injection5 mL USP Type I Amber Glass Ampoule (Box of 5's) | Rx | Gland Pharma LimitedIndia | Endure Medical, Inc. | DR-XY37826 | Apr 23, 2027 | |
FeroseaIron Sucrose (as Ferric Hydroxide Sucrose Complex) | 20 mg/mL (100 mg/5 mL) Solution for IV Injection5 mL USP Type I Amber Glass Ampoule (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Seapharma International, Inc. | DRP-14640 | Nov 9, 2028 | |
FeroxIron Sucrose (As Ferric Hydroxide Sucrose Complex) | 20 mg/mL (100 mg/5ml) Solution For Injection (IV)5 mL Type I Amber Glass Ampoule (Box of 5's) | Rx | Med Biopharm Pvt. Ltd.India | Euroasia Pharmaceuticals, Inc.Importer: Pors Pharma Trading | DRP-16628-01 | Sep 12, 2028 | |
FerriscriptIron (as Iron Sucrose) | 100 mg/5 mL Solution for Injection (I.V.)USP Type I Amber Glass Ampoule x 5 mL (Box of 1 PVC Tray x 5's) | Rx | Swiss Parenterals Ltd. (Block-B)India | Scriptmed, Inc.Importer: Ambica International Corporation | DRP-7844-05 | Jan 26, 2028 | |
FerriscriptIron (as Ferric Hydroxide Sucrose Complex) | 20mg/mL (100mg/5mL) Solution for Injection (I.V.)USP Type I amber glass ampoule x 5mL in a plastic tray (Box of 5's) | Rx | Alwin DMD PharmaceuticalsIndia | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-7111-02 | Mar 17, 2027 | |
FerroferIron Sucrose | 20 mg/mL Solution for Injection (IV)Amber glass ampoule x 5 mL (Box of 5's) | Rx | Nanjing Hencer Pharmaceutical Co., Ltd.China | Goodfellow Pharma Corporation | DR-XY34774 | Aug 6, 2030 | |
FerronfreeIron (as Ferric Hydroxide Sucrose Complex) | 20mg/mL (100mg/5mL) Solution for Injection (I.V.)5 mL USP Type I Amber Glass Ampoule (Box of 5's) | Rx | Alwin DMD PharmaceuticalsIndia | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-7111-09 | Mar 17, 2027 | |
FersucrosIron (as Iron Sucrose) | 100 mg/5 mL Solution for Injection (IV)USP Type I Amber Glass Ampoule x 5 mL (Box of 5's) | Rx | Swiss Parenterals Ltd. (Block-B)India | Diafarm Inc.Importer: Ambica International Corporation | DRP-7844-03 | Jan 26, 2028 | |
FerumcroseIron (as Iron Sucrose) | 100 mg/5 mL Solution for Injection (IV)USP Type I Amber Glass Ampoule x 5 mL (Box of 5's) | Rx | Swiss Parenterals Ltd. (Block-B)India | Multi Product Line Pharma, Inc.Importer: Ambica International Corporation | DRP-7844-04 | Jan 26, 2028 | |
FeruvinIron (As Iron Sucrose) | 20 mg/mL (100mg/5 mL) Solution for Injection (IV)USP Type I amber glass ampoule in PVC plastic tray x 5 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Vintel Med EnterprisesImporter: Afree Pharmaceutical Distribution Corp. | DRP-13888-02 | May 11, 2028 | |
FeruvinIron (as Ferric Hydroxide Sucrose Complex) | 20 mg/mL (100mg/5mL) Solution for Injection (IV)5mL USP Type I amber glass ampoule (Box of 5 ampoules in plastic tray) | Rx | Alwin DMD PharmaceuticalsIndia | Vintel Med EnterprisesImporter: Bliss Pharma Distribution and Consultancy Corp. | DRP-7111-01 | Mar 17, 2027 | |
FridaIron Sucrose | 20 mg/mL Solution For Injection (IV)Usp Type I Clear Glass Ampoule By 5 Ml (Box Of 5'S, 10'S And 25'S) | Rx | Baxter Pharmaceuticals India Private LimitedIndia | UNILAB, Inc.Importer: Baxter Healthcare Philippines, Inc. | DRP-2437-02 | Nov 11, 2027 | |
HEMOSUCROIron Sucrose (as Ferric Hydroxide Sucrose Complex) | 20 mg/mL Solution for Injection (IV)5 mL USP Type I Clear Fiolax Glass Ampoule (Box of 5's) | Rx | Farbe FirmaIndia | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc. | DRP-16452-02 | Mar 14, 2030 | |
HeronseIron (as Iron sucrose) | 20 mg/mL Solution for Injection (IV)USP Type I Amber Glass Ampoule x 5 mL (Box of 5’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant III - Injectables)India | Asterzenmed Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Limited | DRP-10887 | Dec 29, 2031 | |
IfervestIron (as Iron Sucrose) | 20 mg/mL Solution for Injection (I.V.)Type I amber glass ampoule x 5 mL in a PVC plastic tray (Box of 5’s) | Rx | Kamla Lifesciences LtdIndia | Ambica International CorporationTrader: Omnicals Pharma Private Limited | DRP-18933 | Oct 13, 2031 | |
InofarIron Sucrose (Iron III Hydroxide Sucrose Complex) | 20 mg/mL (100 mg/5mL) Solution for Intravenous InfusionUSP Type I Glass Amber Ampoule x 5mL (Box of 2 ampoules) | Rx | Aristopharma Ltd.Bangladesh | Sahar International Trading, Inc. | DRP-4634 | Dec 19, 2027 | |
IroferIron (as Ferric Hydroxide Sucrose Complex) | 20mg/mL (100mg/5mL) Solution for Injection (IV)5 mL USP Type I amber glass ampoule (Box of 5 ampoules in plastic tray) | Rx | Alwin DMD PharmaceuticalsIndia | Genace Pharma DistributorImporter: Bliss Pharma Distribution and Consultancy Corp. | DRP-7111-06 | Mar 17, 2027 | |
IroferoseIron (as Iron Sucrose) | 100 mg/5 mL Solution for Injection (IV)USP Type I Amber Glass Ampoule x 5 mL (Box of 1 PVC Tray x 5's) | Rx | Swiss Parenterals Ltd.India | New Marketlink Pharmaceutical CorporationImporter: Ambica International Corporation | DRP-7844-01 | Jan 26, 2028 | |
IrofreeIron (as Ferric Hydroxide Sucrose Complex) | 20 mg/mL (100mg/5mL) Solution for Injection (IV)5mL USP Type I Amber glass ampoule (Box of 5's in plastic tray) | Rx | Alwin DMD PharmaceuticalsIndia | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-7111-07 | Mar 17, 2027 | |
IromaxIron (as Iron Sucrose) | 20mg/mL Solution For Injection (IV)Type I Glass Ampoule x 5mL (Box of 5's in a plastic tray) | Rx | MAXITECH PHARMA (PVT) LTD.Pakistan | Accesspoint International Trading Inc.Importer: Accesspoint International Trading, Inc. | DRP-14215 | Jul 27, 2028 | |
IronexIron (as Iron Sucrose) | 20 mg / mL Solution for Injection (IV)5 mL USP Type I glass ampoule in PVC tray x 5's (Box of 5’s) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-16053-01 | Dec 10, 2029 | |
IronovaIron Sucrose (as Ferric Hydroxide Sucrose Complex) | 20 mg/mL Solution for Injection (IV)5 mL USP Type I Clear Fiolax Glass Ampoule (Box of 5's) | Rx | Farbe FirmaIndia | Medinova Pharmaceutical Inc. | DRP-16452 | Mar 14, 2030 | |
IronsaveIron (as Iron Sucrose) | 20 mg/mL solution for injection (IV)Type I Glass Ampoule x 5 mL (Box of 5's in a plastic tray) | Rx | Maxitech Pharma (Pvt) Ltd.Pakistan | Savelink Pharma And Trading CoImporter: Accesspoint International Trading Inc. | DRP-14215-01 | Jul 27, 2028 | |
IronseIron (as Iron sucrose) | 20 mg/mL Solution for Injection (IV)USP Type I Amber Glass Ampoule x 5 mL (Box of 5’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant III - Injectables)India | CDM Marketing CenterImporter: Ambica International CorporationTrader: Unosource Pharma Limited | DRP-10886 | Dec 29, 2031 | |
IrophilIron (as Iron sucrose) | 100 mg/5 mL Solution for Injection (I.V.)USP Type I amber glass ampoule x 5 mL in a plastic tray (Box of 5's) | Rx | Ratnaris Pharmaceuticals Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-17550 | Jan 26, 2031 | |
IroxariIron Sucrose (as Ferric Hydroxide Sucrose Complex) | 20 mg/mL (100 mg/5 mL) Solution for I.V. InjectionType I Amber colored glass ampoule x 5 mL (Box of 5's) | Rx | Pharmax India Private LimitedIndia | Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-15313 | Jul 2, 2029 | |
IrsucIron (as Ferric Hydroxide Sucrose Complex) | 20 mg / mL (100 mg / 5 mL) Solution for Injection (IV)5 mL Amber Glass Ampoule (Box of 5’s) | Rx | Zee Laboratories LimitedHimachal Pradesh India | One Pharma Marketing Inc.Importer: Eon Pharmatek Inc. | DRP-15056-01 | Oct 5, 2027 | |
IRSUCIron (as Iron Sucrose) | 20 mg/mL (100mg/5 mL) Solution for Injection (IV)USP Type I amber glass ampoule in PVC plastic tray x 5 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | One Pharma Marketing Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-13888-07 | May 11, 2028 | |
IrsucIron (as Ferric Hydroxide Sucrose Complex) | 20 mg/mL (100mg/5mL) Solution for Injection (IV)5 mL USP Type I Amber glass ampoule (Box of 5's) | Rx | Alwin DMD PharmaceuticalsIndia | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-7111-08 | Mar 17, 2027 | |
IseronIron Sucrose | 20 mg/mL (100 mg/5 mL) Solution for Injection (IV)5 mL USP Type I Amber Glass Ampoule (Box of 5's) | Rx | Swiss Parenterals Ltd.India | Endure Medical, Inc. | DR-XY42932 | Nov 13, 2028 | |
IsucrinIron Sucrose | 20 mg/mL Solution for Intravenous (I.V.) InjectionUSP Type I Amber Glass Ampoule x 5 mL (Box of 5’s) | Rx | Mason PharmaIndia | Ellebasy Medicale Group Inc.Importer: Finstad Inc. | DRP-12662-03 | Sep 20, 2027 | |
IsuferIron (as Iron Sucrose) | 20 mg/mL (100 mg/5 mL) Solution for Injection (IV)USP Type I amber glass ampoule in PVC plastic tray x 5 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | GPC Geo Pharma CorporationImporter: Afree Pharmaceutical Distribution Corp. | DRP-13888-04 | May 11, 2028 | |
IsuferIron (as Ferric Hydroxide Sucrose Complex) | 20 mg/mL (100mg/5mL) Solution for Injection (IV)5mL USP Type I amber glass ampoule (Box of 5 ampoules in plastic tray) | Rx | Alwin DMD PharmaceuticalsIndia | GPC Geo Pharma CorporationImporter: Bliss Pharma Distribution and Consultancy Corp. | DRP-7111-03 | Mar 17, 2027 | |
MaxiferIron Sucrose | 20 mg/mL (100mg/5mL) Solution for Injection (IV)USP Type I clear colorless glass ampoule x 5 mL (Box of 5's) | Rx | Gland Pharma PrivateIndia | Multicare Pharmaceuticals Philippines, Inc.Importer: Biocare Lifesciences, Inc. | DRP-5540-02 | May 6, 2031 | |
MedoferIron sucrose | 20 mg/mL (100 mg/5 mL) Solution for Injection (IV)USP Type I Clear Glass Ampoule x 5 mL m a Clear PVC Plastic Tray x 5 's (Box of 5' s) | Rx | Samrudh Pharmaceuticals Pvt. Ltd.India | Helande Kidney Care lnc.Importer: I.E. Medica, Inc. | DRP-7926 | Sep 2, 2031 | |
MesoferIron Sucrose | 20mg/mL Solution for Intravenous (I.V.) Injection5 ml Amber USP Type-I Glass Ampoules (Box of 5's) | Rx | Mason PharmaIndia | Finstad, Inc. | DRP-12662 | Sep 20, 2027 | |
NoneIron (as Iron Sucrose) | 20 mg/mL (100 mg/5 mL) Solution for Injection (IV)USP Type I amber glass ampoule in PVC plastic tray x 5 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | One Pharma Marketing Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-13888-05 | May 11, 2028 | |
NoneIron (as Iron Sucrose) | 20 mg/mL (100 mg/5 mL) Solution for Injection (IV)USP Type I Amber Glass ampoule in PVC plastic tray x 5 mL (Box of 5's) | Rx | Makcur laboratories LimitedIndia | Medinova Pharmaceutical Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-13888-06 | May 11, 2028 | |
NoneIron (as Iron Sucrose) | 20 mg/mL (100mg/5 mL) Solution for Injection (IV)USP Type I Amber Glass ampoule in PVC Plastic tray x 5 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Genace Pharma DistributorImporter: Afree Pharmaceutical Distribution Corp. | DRP-13888-01 | May 11, 2028 | |
NoneIron (as Iron sucrose) | 20 mg/mL Solution for Injection (IV)Type I Glass Ampoule x 5mL (Box of 5's in a plastic tray) | Rx | Maxitech Pharma (Pvt.) Ltd.Pakistan | Rexmed Pharmaceutical SalesImporter: Accesspoint International Trading Inc. | DRP-14215-02 | Jul 27, 2028 | |
NoneIron (as Iron sucrose) | 20 mg/mL Solution for Injection (IV)Type I Glass Ampoule x 5mL (Box of 5's in plastic tray) | Rx | Maxitech Pharma (Pvt.) Ltd.Pakistan | Reta DrugImporter: Accesspoint International Trading Inc. | DRP-14215-04 | Jul 27, 2028 | |
PorsroseIron Sucrose (as Ferric Hydroxide Sucrose Complex) | 20 mg/mL (100 mg/5 mL) Solution for Injection (IV)5 mL Type I Amber Glass Ampoule (Box of 5's) | Rx | Med Biopharm Pvt. Ltd.India | Pors Pharma Trading | DR-XY48874 | Sep 12, 2028 | |
PorsroseIron Sucrose (As Ferric Hydroxide Sucrose Complex) | 20 mg/mL(100 Mg/5ml) Solution For Injection (Iv)5 mL Type I Amber Glass Ampoule (Box of 5's) | Rx | Med Biopharm Pvt. Ltd.India | Pors Pharma Trading | DRP-16628 | Sep 12, 2028 | |
RanoferIron (As Iron Sucrose) | 20 mg/mL (100mg/5 mL) Solution for Injection (I.V.)5 mL Type I Amber glass ampoules (Box of 5's) | Rx | Duopharma (M) Sdn. Bhd.Malaysia | DB (Philippines), Inc. | DR-XY48113 | Jun 17, 2027 | |
RetaroneIron (as Iron Sucrose) | 20 mg/mL (100 mg/5 mL) Solution for Injection (IV)USP Type I amber glass ampoule in PVC plastic tray x 5 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Reta DrugImporter: Afree Pharmaceutical Distribution Corp. | DRP-13888-08 | May 11, 2028 | |
SaluFerIron Sucrose | 20 mg/mL Solution for Intravenous (I.V.) InjectionUSP Type I, Amber Glass Ampoule x 5 mL (Box of 5's) | Rx | Mason PharmaIndia | Salusa Medical Supplies And Pharmaceuticals Inc.Importer: Finstad Inc. | DRP-12662-02 | Sep 20, 2027 | |
SironIron Sucrose | 20 mg/mL Solution for Intravenous (I.V.) InjectionUSP Type I Amber Glass Ampoule x 5 mL (Box of 5's) | Rx | Mason PharmaIndia | JL Dialmed Trading Co.Importer: Finstad, Inc. | DRP-12662-04 | Sep 20, 2027 | |
SucroferIron Sucrose | 20 mg/mL Solution For Injection (IV)Usp Type I Clear Glass Ampoule By 5 Ml (Box Of 5'S, 10'S And 25'S) | Rx | Baxter Pharmaceuticals India Private LimitedIndia | Importer: Baxter Healthcare Philippines, Inc. | DRP-2437 | Nov 11, 2027 | |
SucronavIron Sucrose (as Ferric Hydroxide Sucrose Complex) | 20 mg/mL Solution for Injection (IV)5 mL USP Type I Clear Fiolax Glass Ampoule (Box of 5's) | Rx | Farbe FirmaIndia | JN Carlo Pharmaceuticals DistributorImporter: Medinova Pharmaceutical Inc. | DRP-16452-01 | Mar 14, 2030 | |
SucrosaphIron (as Iron Sucrose) | 20 mg/mL (100 mg/5 mL) Solution for Injection (I.V.)Type I Amber Glass Ampoule x 5 mL (Box of 5's) | Rx | Kilitch Drug (India) Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences, Pvt. Ltd. | DRP-13241 | Dec 11, 2030 | |
SucrostarIron (as iron sucrose) | 20 mg/mL Solution for Injection (I.V.)Amber Ampoule | Rx | Aculife Healthcare Private LimitedIndia | Blue Global (FZE) | DRP-15679 | Aug 20, 2029 | |
SucruferIron (as Iron sucrose) | 20 mg/mL Solution for Injection (IV)Type I Glass Ampoule x 5mL (Box of 5's in a plastic tray) | Rx | Maxitech Pharma (Pvt.) Ltd.Pakistan | FERJAN PHILIPPINES INC.Importer: Accesspoint International Trading Inc. | DRP-14215-03 | Jul 27, 2028 | |
SurconIron Sucrose (as Ferric Hydroxide Sucrose Complex) | 20 mg/mL (100 mg/5 mL) Solution for Injection (IV)5 mL USP Type I Amber Glass Ampoule in a PVC Tray x 5's (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Pharma-Surrey International Inc. | DRP-16391 | Feb 26, 2030 | |
VenroseIron [as Ferric hydroxide sucrose complex] | 20 mg/mL (100 mg/5 mL) Concentrate for Solution for Injection (I.V. Infusion)5 mL Type I amber glass ampoule (Box of 5's) | Rx | Mefar Ilac Sanayii A.S.Turkey | Ambica International CorporationTrader: Pharmada Ilac San. Ve Tic. A.S. | DRP-10297 | Sep 9, 2031 | |
Zypiron 20Iron (as Ferric hydroxide sucrose complex) | 20 mg/mL (100 mg/5 mL) Lyophilized Powder For Injection (Iv)5 mL Clear USP Type I moulded glass vial (Box of 5's ); Box of 5's as Physician's sample | Rx | Cadila Healthcare LimitedIndia | Zydus Healthcare Philippines Inc. | DRP-11619 | Apr 4, 2027 | |
(no brand name)Iron Sucrose | 363.64 mg/mL (equivalent to 20 mg elemental Iron) Solution for Injection (I.V.)USP Type I flint moulded glass vial with 20 mm grey bromobutyl rubber stopper closure and 20 mm light blue flip-off aluminum seal x 5 mL and 10 mL (Box of l's) | Rx | Mylan Laboratories Limited (Hosur Sterile Facility)India | Mylan Philippines Inc. | DRP-11142 | Feb 7, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Injection: 100 mg/5 mL (20 mg/mL) in single-dose vials. (3) Injection: 100 mg/5 mL (20 mg/mL) in single-dose vials.
Warnings/Precautions
- Hypersensitivity Reactions: Observe for signs and symptoms of hypersensitivity during and after Venofer administration for at least 30 minutes and until clinically stable following completion of each administration. Only administer Venofer when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. (5.1)
- Hypotension: May cause hypotension. Monitor for signs and symptoms of hypotension during and following each administration. (5.2)
- Iron Overload: Regularly monitor hematologic responses during therapy. Do not administer to patients with iron overload. (5.3)
5.1 Hypersensitivity Reactions
5.1 Hypersensitivity Reactions Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Venofer. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. If hypersensitivity reactions or signs of intolerance occur during administration, stop Venofer immediately.
Monitor patients for signs and symptoms of hypersensitivity during and after Venofer administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Venofer when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions.
Most reactions associated with intravenous iron preparations occur within 30 minutes of the completion of the infusion [see Adverse Reactions (6.1 and 6.2)].
5.2 Hypotension
5.2 Hypotension Venofer may cause clinically significant hypotension. Monitor for signs and symptoms of hypotension following each administration of Venofer. Hypotension following administration of Venofer may be related to the rate of administration and/or total dose administered [see Dosage and Administration (2), Warnings and Precautions (5.1), and Adverse Reactions (6.2)].
5.3 Iron Overload
5.3 Iron Overload Excessive therapy with parenteral iron can lead to excess storage of iron with the possibility of iatrogenic hemosiderosis. All adult and pediatric patients receiving Venofer require periodic monitoring of hematologic and iron parameters (hemoglobin, hematocrit, serum ferritin and transferrin saturation).
Do not administer Venofer to patients with evidence of iron overload. Transferrin saturation (TSAT) values increase rapidly after intravenous administration of iron sucrose; do not perform serum iron measurements for at least 48 hours after intravenous dosing [see Dosage and Administration (2) and Overdosage (10)].
Drug interactions
Drug interactions (US label) US FDA label
7 DRUG INTERACTIONS Venofer may reduce the absorption of concomitantly administered oral iron preparations.
Adverse reactions
- The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Hypotension [see Warnings and Precautions (5.2)] Iron Overload [see Warnings and Precautions (5.3)] Adult patients: The most common adverse reactions (≥2%) are diarrhea, nausea, vomiting, headache, dizziness, hypotension, pruritus, pain in extremity, arthralgia, back pain, muscle cramp, injection site reactions, chest pain, and peripheral edema. (6.1)
- Pediatric patients: The most common adverse reactions (≥2%) are headache, respiratory tract viral infection, peritonitis, vomiting, pyrexia, dizziness, cough, nausea, arteriovenous fistula thrombosis, hypotension, and hypertension. (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact American Regent, Inc. at 1-800-734-9236 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Adverse Reactions in Clinical Trials
6.1 Adverse Reactions in Clinical Trials Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug may not reflect the rates observed in practice. Adverse Reactions in Adults Patients with CKD The frequency of adverse reactions associated with the use of Venofer has been documented in six clinical trials involving 231 patients with HDD-CKD, 139 patients with NDD-CKD and 75 patients with PDD-CKD.
Adverse reactions reported by ≥ 2% of treated patients in the six clinical trials for which the rate for Venofer exceeds the rate for comparator are listed by indication in Table 1. Patients with HDD-CKD received 100 mg doses at 10 consecutive dialysis sessions until a cumulative dose of 1000 mg was administered. Patients with NDD-CKD received either 5 doses of 200 mg over 2 weeks or 2 doses of 500 mg separated by fourteen days, and patients with PDD-CKD received 2 doses of 300 mg followed by a dose of 400 mg over a period of 4 weeks.
Table 1. Adverse Reactions Reported in ≥ 2% of Study Populations and for which the Rate for Venofer Exceeds the Rate for Comparator * EPO=Erythropoietin Body System/Adverse Reactions HDD-CKD NDD-CKD PDD-CKD Venofer Venofer Oral Iron Venofer EPO* Only (N=231) (N=139) (N=139) (N=75) (N=46) % % % % % Subjects with any adverse reaction 78.8 76.3 73.4 72.0 65.2 Ear and Labyrinth Disorders Ear Pain 0 2.2 0.7 0 0 Eye Disorders Conjunctivitis 0.4 0 0 2.7 0 Gastrointestinal Disorders Abdominal pain 3.5 1.4 2.9 4.0
6.5 Diarrhea 5
6.5 Diarrhea 5.2 7.2 10.1 8.0 4.3 Dysgeusia 0.9 7.9 0 0 0 Nausea 14.7 8.6 12.2 5.3 4.3 Vomiting 9.1 5.0 8.6 8.0 2.2 General Disorders and Administration Site Conditions Asthenia 2.2 0.7 2.2 2.7 0 Chest pain 6.1 1.4 0 2.7 0 Feeling abnormal 3.0 0 0 0 0 Infusion site pain or burning 0 5.8 0 0 0 Injection site extravasation 0 2.2 0 0 0 Peripheral edema 2.6 7.2 5.0 5.3 10.9 Pyrexia 3.0 0.7 0.7 1.3 0 Infections and Infestations Nasopharyngitis, Sinusitis, Upper respiratory tract infections, Pharyngitis 2.6 2.2 4.3 16.0 4.3 Injury, Poisoning and Procedural Complications Graft complication 9.5 1.4 0 0 0 Metabolism and Nutrition Disorders Fluid overload 3.0 1.4 0.7 1.3 0 Gout 0 2.9 1.4 0 0 Hyperglycemia 0 2.9 0 0 2.2 Hypoglycemia 0.4 0.7 0.7 4.0 0 Musculoskeletal and Connective Tissue Disorders Arthralgia 3.5 1.4 2.2 4.0 4.3 Back pain 2.2 2.2 3.6 1.3 4.3 Muscle cramp 29.4 0.7 0.7 2.7 0 Myalgia 0 3.6 0 1.3 0 Pain in extremity 5.6 4.3 0 2.7
6.5 Nervous System Disorders Dizziness 6
6.5 Nervous System Disorders Dizziness 6.5 6.5 1.4 1.3 4.3 Headache 12.6 2.9 0.7 4.0 0 Respiratory, Thoracic and Mediastinal Disorders Cough 3.0 2.2 0.7 1.3 0 Dyspnea 3.5 5.8 1.4 1.3 2.2 Nasal congestion 0 1.4 2.2 1.3 0 Skin and Subcutaneous Tissue Disorders Pruritus 3.9 2.2 4.3 2.7 0 Vascular Disorders Hypertension 6.5 6.5 4.3 8.0
6.5 Hypotension 39
6.5 Hypotension 39.4 2.2 0.7 2.7 2.2 One hundred thirty (11%) of the 1,151 patients evaluated in the 4 U.S. trials in HDD-CKD patients (studies A, B and the two post marketing studies) had prior other intravenous iron therapy and were reported to be intolerant (defined as precluding further use of that iron product). When these patients were treated with Venofer there were no occurrences of adverse reactions that precluded further use of Venofer [see Warning and Precautions (5)].
Adverse Reactions in Pediatric Patients with CKD (ages 2 years and older) In a randomized, open-label, dose-ranging trial for iron maintenance treatment with Venofer in pediatric patients with CKD on stable erythropoietin therapy [see Clinical Studies (14.7)], at least one adverse reaction was experienced by 57% (27/47) of the patients receiving Venofer 0.5 mg/kg, 53% (25/47) of the patients receiving Venofer 1 mg/kg, and 55% (26/47) of the patients receiving Venofer 2 mg/kg. A total of 5 (11%) subjects in the Venofer 0.5 mg/kg group, 10 (21%) patients in the Venofer 1 mg/kg group, and 10 (21%) patients in the Venofer 2 mg/kg group experienced at least 1 serious adverse reaction during the study.
The most common adverse reactions (>2% of patients) in all patients were headache (6%), respiratory tract viral infection (4%), peritonitis (4%), vomiting (4%), pyrexia (4%), dizziness (4%), cough (4%), nausea (3%), arteriovenous fistula thrombosis (2%), hypotension (2%), and hypertension (2.1%).
6.2 Adverse Reactions from Post-Marketing Experience
6.2 Adverse Reactions from Post-Marketing Experience The following adverse reactions have been identified during post-approval use of Venofer. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
In the post-marketing safety studies in 1,051 treated patients with HDD-CKD, the adverse reactions reported by >1% were cardiac failure congestive, sepsis and dysgeusia. Immune system disorders: anaphylactic-type reactions, angioedema Psychiatric disorders: confusion Nervous system disorders: convulsions, collapse, light-headedness, loss-of-consciousness Cardiovascular System: bradycardia, shock, acute myocardial ischemia with or without myocardial infarction or with in-stent thrombosis in the context of a hypersensitivity reaction.
Respiratory, thoracic and mediastinal disorders: bronchospasm, dyspnea Musculoskeletal and connective tissue disorders: back pain, swelling of the joints Renal and urinary disorders: chromaturia General disorders and administration site conditions: hyperhidrosis Symptoms associated with Venofer total dosage or infusing too rapidly included hypotension, dyspnea, headache, vomiting, nausea, dizziness, joint aches, paresthesia, abdominal and muscle pain, edema, and cardiovascular collapse. These adverse reactions have occurred up to 30 minutes after the administration of Venofer injection.
Reactions have occurred following the first dose or subsequent doses of Venofer. Symptoms may respond to intravenous fluids, hydrocortisone, and/or antihistamines. Slowing the infusion rate may alleviate symptoms. Injection site discoloration has been reported following extravasation. Assure stable intravenous access to avoid extravasation.
Adverse reaction frequency tables (US label) US FDA label
| * EPO=Erythropoietin | |||||
| Body System/Adverse Reactions | HDD-CKD | NDD-CKD | PDD-CKD | ||
| Venofer | Venofer | Oral Iron | Venofer | EPO* Only | |
| (N=231) | (N=139) | (N=139) | (N=75) | (N=46) | |
| % | % | % | % | % | |
| Subjects with any adverse reaction | 78.8 | 76.3 | 73.4 | 72.0 | 65.2 |
| Ear and Labyrinth Disorders | |||||
| Ear Pain | 0 | 2.2 | 0.7 | 0 | 0 |
| Eye Disorders | |||||
| Conjunctivitis | 0.4 | 0 | 0 | 2.7 | 0 |
| Gastrointestinal Disorders | |||||
| Abdominal pain | 3.5 | 1.4 | 2.9 | 4.0 | 6.5 |
| Diarrhea | 5.2 | 7.2 | 10.1 | 8.0 | 4.3 |
| Dysgeusia | 0.9 | 7.9 | 0 | 0 | 0 |
| Nausea | 14.7 | 8.6 | 12.2 | 5.3 | 4.3 |
| Vomiting | 9.1 | 5.0 | 8.6 | 8.0 | 2.2 |
| General Disorders and | |||||
| Administration Site Conditions | |||||
| Asthenia | 2.2 | 0.7 | 2.2 | 2.7 | 0 |
| Chest pain | 6.1 | 1.4 | 0 | 2.7 | 0 |
| Feeling abnormal | 3.0 | 0 | 0 | 0 | 0 |
| Infusion site pain or burning | 0 | 5.8 | 0 | 0 | 0 |
| Injection site extravasation | 0 | 2.2 | 0 | 0 | 0 |
| Peripheral edema | 2.6 | 7.2 | 5.0 | 5.3 | 10.9 |
| Pyrexia | 3.0 | 0.7 | 0.7 | 1.3 | 0 |
| Infections and Infestations | |||||
| Nasopharyngitis, Sinusitis, Upper respiratory tract infections, Pharyngitis | 2.6 | 2.2 | 4.3 | 16.0 | 4.3 |
| Injury, Poisoning and Procedural | |||||
| Complications | |||||
| Graft complication | 9.5 | 1.4 | 0 | 0 | 0 |
| Metabolism and Nutrition Disorders | |||||
| Fluid overload | 3.0 | 1.4 | 0.7 | 1.3 | 0 |
| Gout | 0 | 2.9 | 1.4 | 0 | 0 |
| Hyperglycemia | 0 | 2.9 | 0 | 0 | 2.2 |
| Hypoglycemia | 0.4 | 0.7 | 0.7 | 4.0 | 0 |
| Musculoskeletal and Connective | |||||
| Tissue Disorders | |||||
| Arthralgia | 3.5 | 1.4 | 2.2 | 4.0 | 4.3 |
| Back pain | 2.2 | 2.2 | 3.6 | 1.3 | 4.3 |
| Muscle cramp | 29.4 | 0.7 | 0.7 | 2.7 | 0 |
| Myalgia | 0 | 3.6 | 0 | 1.3 | 0 |
| Pain in extremity | 5.6 | 4.3 | 0 | 2.7 | 6.5 |
| Nervous System Disorders | |||||
| Dizziness | 6.5 | 6.5 | 1.4 | 1.3 | 4.3 |
| Headache | 12.6 | 2.9 | 0.7 | 4.0 | 0 |
| Respiratory, Thoracic and | |||||
| Mediastinal Disorders | |||||
| Cough | 3.0 | 2.2 | 0.7 | 1.3 | 0 |
| Dyspnea | 3.5 | 5.8 | 1.4 | 1.3 | 2.2 |
| Nasal congestion | 0 | 1.4 | 2.2 | 1.3 | 0 |
| Skin and Subcutaneous | |||||
| Tissue Disorders | |||||
| Pruritus | 3.9 | 2.2 | 4.3 | 2.7 | 0 |
| Vascular Disorders | |||||
| Hypertension | 6.5 | 6.5 | 4.3 | 8.0 | 6.5 |
| Hypotension | 39.4 | 2.2 | 0.7 | 2.7 | 2.2 |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Published studies on intravenous iron sucrose treatment after the first trimester of pregnancy have not shown adverse maternal or fetal outcomes (see Data). Available reports of intravenous iron sucrose use in pregnant women during the first trimester are insufficient to assess the risk of major birth defects and miscarriage.
There are risks to the mother and fetus associated with untreated IDA in pregnancy as well as risks to the fetus associated with maternal severe hypersensitivity reactions (see Clinical Considerations). Animal reproduction studies of iron sucrose administered to rats and rabbits during the period of organogenesis at elemental iron doses equivalent to the maximum recommended human dose based on body surface area revealed no evidence of harm to the fetus (see Data).
The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically-recognized pregnancies is 2-4% and 15-20%, respectively.
Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Iron deficiency anemia during pregnancy should be treated. Untreated IDA in pregnancy is associated with adverse maternal outcomes such as post-partum anemia. Adverse pregnancy outcomes associated with IDA include increased risk for preterm delivery and low birth weight.
Fetal/Neonatal adverse reactions Severe adverse reactions including circulatory failure (severe hypotension, shock including in the context of anaphylactic reaction) may occur in pregnant women with parenteral iron products (such as Venofer) which may cause fetal bradycardia, especially during the second and third trimester. Data Human Data Published data from randomized controlled studies and prospective observational studies on the use of Venofer in pregnant women have not reported an association of Venofer and adverse developmental outcomes.
However, these studies did not include women exposed during the first trimester of pregnancy and were not designed to assess the risk of major birth defects. Maternal adverse events reported in these studies are similar to those reported during clinical trials in adult males and non-pregnant females [see Adverse Reactions (6.1)].
Animal Data Iron sucrose was administered intravenously to rats and rabbits during the period of organogenesis at elemental iron doses up to 13 mg/kg/day (0.25 times or equivalent to the maximum recommended human dose based on body surface area, respectively) and revealed no evidence of harm to the fetus.
Mechanism of action
12.1 Mechanism of Action Venofer is an aqueous complex of poly-nuclear iron (III)-hydroxide in sucrose. Following intravenous administration, Venofer is dissociated into iron and sucrose and the iron is transported as a complex with transferrin to target cells including erythroid precursor cells. The iron in the precursor cells is incorporated into hemoglobin as the cells mature into red blood cells.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Following intravenous administration, Venofer is dissociated into iron and sucrose. In 22 patients undergoing hemodialysis and receiving erythropoietin (recombinant human erythropoietin) therapy treated with iron sucrose containing 100 mg of iron, three times weekly for three weeks, significant increases in serum iron and serum ferritin and significant decreases in total iron binding capacity occurred four weeks from the initiation of iron sucrose treatment.
Pharmacokinetics
12.3 Pharmacokinetics In healthy adults administered intravenous doses of Venofer, its iron component exhibited first order kinetics with an elimination half-life of 6 h, total clearance of 1.2 L/h, and steady state apparent volume of distribution of 7.9 L.
The sucrose component is eliminated mainly by urinary excretion.
In a study evaluating a single intravenous dose of Venofer containing 1,510 mg of sucrose and 100 mg of iron in 12 healthy adults (9 female, 3 male: age range 32 to 52), 68.3% of the sucrose was eliminated in urine in 4 h and 75.4% in 24 h.
Some iron was also eliminated in the urine.
In this study and another study evaluating a single intravenous dose of iron sucrose containing 500 to 700 mg of iron in 26 patients with anemia on erythropoietin therapy (23 female, 3 male; age range 16 to 60), approximately 5% of the iron was eliminated in urine in 24 h at each dose level.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics In healthy adults administered intravenous doses of Venofer, its iron component exhibited first order kinetics with an elimination half-life of 6 h, total clearance of 1.2 L/h, and steady state apparent volume of distribution of 7.9 L. The iron component appeared to distribute mainly in blood and to some extent in extravascular fluid.
A study evaluating Venofer containing 100 mg of iron labeled with 52 Fe/ 59 Fe in patients with iron deficiency showed that a significant amount of the administered iron is distributed to the liver, spleen and bone marrow and that the bone marrow is an irreversible iron trapping compartment. Following intravenous administration of Venofer, iron sucrose is dissociated into iron and sucrose.
The sucrose component is eliminated mainly by urinary excretion. In a study evaluating a single intravenous dose of Venofer containing 1,510 mg of sucrose and 100 mg of iron in 12 healthy adults (9 female, 3 male: age range 32 to 52), 68.3% of the sucrose was eliminated in urine in 4 h and 75.4% in 24 h. Some iron was also eliminated in the urine.
Neither transferrin nor transferrin receptor levels changed immediately after the dose administration. In this study and another study evaluating a single intravenous dose of iron sucrose containing 500 to 700 mg of iron in 26 patients with anemia on erythropoietin therapy (23 female, 3 male; age range 16 to 60), approximately 5% of the iron was eliminated in urine in 24 h at each dose level.
The effects of age and gender on the pharmacokinetics of Venofer have not been studied. Pharmacokinetics in Pediatric Patients In a single-dose PK study of Venofer, patients with NDD-CKD ages 12 to 16 (N=11) received intravenous bolus doses of Venofer at 7 mg/kg (maximum 200 mg) administered over 5 minutes. Following a single dose of Venofer, the half-life of total serum iron was 8 hours.
The mean Cmax and AUC values were 8545 μg/dl and 31305 hr•μg/dL, respectively, which were 1.42- and 1.67-fold higher than dose adjusted adult Cmax and AUC values. Venofer is not dialyzable through CA210 (Baxter) High Efficiency or Fresenius F80A High Flux dialysis membranes. In in vitro studies, the amount of iron sucrose in the dialysate fluid was below the levels of detection of the assay (less than 2 parts per million).
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Iron Sucrose 20 mg/mL, 5 mL Ampule | ₱85.10–₱288.00Reference ₱111.56 | per ampule | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Iron sucrose |
| PNF listing | Inj.: 20 mg/mL, 5 mL ampule |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Venofer · American Regent, Inc. [US FDA-approved label, version 12, March 1, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b998ef36-81fa-40a1-9cd1-6d6156f91564
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .